MARKET

ALPMF

ALPMF

Astellas Pharma
OTCPK
16.55
NaN%
Closed 09:30 11/13 EST
OPEN
--
PREV CLOSE
16.00
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
39.03
52 WEEK LOW
16.00
MARKET CAP
29.68B
P/E (TTM)
12.04
1D
5D
1M
3M
1Y
5Y
1D
AstraZeneca gains additional bladder cancer indication for Imfinzi
Seeking Alpha · 1d ago
Weekly Report: what happened at ALPMF last week (1102-1106)?
Weekly Report · 5d ago
Astellas Pharma (ALPMF) Receives a Hold from Morgan Stanley
TipRanks · 11/05 10:06
Astellas Pharma (ALPMF) Receives a Buy from Macquarie
TipRanks · 11/05 10:05
Astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook
Seeking Alpha · 11/04 07:38
Astellas Tests Hot-Flash Drug in India, Opening a Potential New Market
TipRanks · 11/02 16:30
Weekly Report: what happened at ALPMF last week (1026-1030)?
Weekly Report · 11/02 09:49
Pfizer Talzenna/Xtandi combo approved for earlier prostate cancer setting
Seeking Alpha · 10/26 22:06
More
About ALPMF
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMF stock methods without spending real money on the virtual paper trading platform.